
EBR Systems has fallen sharply after a major capital raise sparked dilution concerns. Despite the sell-off, the company continues to expand the commercialisation of its FDA-approved WiSE CRT heart-failure technology, supported by growing implant volumes, clinical studies, and international regulatory progress.

SRJ Technologies has attracted strong investor interest following the securing of multiple energy-sector contracts, including major UAE robotic inspection projects. Growing adoption of BoltEx® technology, expanding Middle East operations, and a strengthening recurring revenue pipeline have boosted confidence in the company's growth outlook.

Ardea Resources (ASX: ARL) is an Australian critical minerals developer whose stock has pulled back sharply from 2026 highs, pressured by a DFS delay at its world-class Kalgoorlie Nickel Project, weak nickel prices, and thin institutional support, while technical indicators suggest the $0.50 level may act as a key support floor.

Hammer Metals, a junior explorer focused on copper, gold and lithium in Queensland and WA, broke above resistance on strong Kalman drilling and a trading halt tied to a potential control deal, though overbought technicals and exploration risk remain.

Alterity Therapeutics (ASX: ATH) is advancing its lead neurodegeneration drug, ATH434, toward Phase 3 trials. Following positive clinical data and a 1-for-50 share consolidation, the stock is holding key technical support around 0.450, awaiting a potential upside breakout.

DXN's share price surged from 2 cents to 14 cents in 2026 after winning major AI and telecommunications infrastructure contracts. The modular data centre specialist is expanding globally, with investors betting on strong growth from AI, cloud, and digital infrastructure markets.